Drug Discovery Featured Articles & Applications

  1. 10 Critical Components Of A Successful Global Drug Development Plan
    9/30/2016

    We use plans every day to help us arrive at our desired destinations.  Pilots utilize flight plans prior to take off — although they have flown to their destination perhaps hundreds of times before, they nevertheless reviews and follows a flight plan. Likewise, ship’s captains also file plans and chart courses. Road maps provide guidance on how to drive from point A to point B, though today most people rely on electronic global positioning systems (GPS) to assist with navigation.

  2. Opioid Crisis Pushing Changes To U.S. Chronic Pain Drug Market
    9/26/2016

    With the U.S opioid analgesic addiction and overdose crisis showing no signs of relenting, change is coming fast for manufacturers of chronic pain drugs.

  3. From Discovery To Development: GS Expression System For Next-Generation Biologics
    9/14/2016

    Compared to traditional antibody expression, where routine purification and analytical strategies have been established over the last few years, next-generation biologics have complex designs. If you are first in class or you have a very bespoke up- and downstream process, it also means you will have bigger hurdles to overcome when it comes to regulatory support and filing. At Lonza, these challenges are addressed with the GS™ expression platform.

  4. Digging Into The Details: Commonly Asked Questions About Lonza’s XS And GS Expression Systems
    9/14/2016

    No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. Experts from Lonza answers questions about the proprietary expression platforms the company has assembled to rapidly generate high-producing cell lines for biological candidates.

  5. Speed Up The Pace Of Chemical Research And Development
    9/12/2016

    Today’s chemical development labs are busy places that create fascinating new chemicals, new formulations and new products that boost the bottom line. But are these labs as efficient as they could be?

  6. Is Automation The Disruption Pharma R&D Needs?
    9/6/2016

    According to a recent report from PhRMA, U.S. biopharmaceutical companies spend more than 13 times the amount of R&D per employee than all other manufacturing industries.

  7. Improving Green Chemistry With An Electronic Lab Notebook
    9/2/2016
    The drive toward sustainable, “green” processes in biopharmaceuticals seems like a daunting challenge. However, the right tools can integrate “green” practices into every aspect of the development workflow. This case study explores how one BIOVIA customer rolled out BIOVIA Workbook across its process chemistry division to around 1,000 scientists and the “green” benefits the group saw.
  8. How Pacira Pharma Is Working To Help Curb The Opioid Epidemic
    8/31/2016

    The most effective way to stop the epidemic of opioid dependence is to eliminate the use of these highly addictive drugs after surgery. This was the goal of Pacira Pharmaceuticals, a specialty pharmaceutical company focused on the development of non-opioid products for postsurgical pain control, when it developed its injectable suspension, EXPAREL®.

  9. Early Implementation Of Quality By Design For Biological Product Development
    8/18/2016

    The idea of thinking in terms of “operational excellence” is a relatively new idea for the biopharmaceutical industry. The enormous uncertainty associated with bringing a biological drug product from discovery to approval almost precludes the thought of forward-thinking in terms of what makes a quality product, especially during early-stage development. However, extensive product knowledge is gathered during early development, and crucial decisions are made in terms moving the science forward to generate the data required to meet your business objectives.

  10. Continuous Processing Optimization With Smarter Tools
    8/17/2016

    Due to a paradigm shift in the pharmaceutical industry, there is rising pressure to come up with faster, more cost-effective ways to produce drugs for the patients who need them.